Abstract: The present invention concerns compositions and processes that use affinity tags for isolating, and detecting or quantifying analytes, including nucleic acids, proteins and polypeptides. Compositions include nucleic acid compositions and protein compositions with affinity binding pairs, including metal binding peptides and immobilized metals, or peptide affinity groups.
Type:
Application
Filed:
March 29, 2021
Publication date:
July 15, 2021
Applicant:
Enzo Biochem, Inc.
Inventors:
Elazar Rabbani, Jannis G. Stavrianopoulos, James J. Donegan, Wayne Patton, Juan Carcamo, Jack Coleman
Abstract: The invention provides methods and compositions for treating cancers and myeloproliferative disorders using sphingosine kinase-1 inhibitors, such as SK1-I, and selective sphingosine-1-phosphate receptor agonists, such as ozanimod.
Abstract: Provided is a protein comprising an antibody binding site that binds to a sulfated epitope of a Wnt pathway protein that is not Wnt5A, Wnt11, or Wnt3a. In one embodiment, the Wnt pathway protein is the Dickkopf1 (Dkk1) protein. Further provided is a composition comprising a peptide less than 75 amino acids or amino acid analogs, the peptide consisting of a fragment of a Wnt pathway protein, such as a Dkk1, wherein the fragment is sulfated.
Abstract: The present invention concerns compositions and processes that use affinity tags for isolating, and detecting or quantifying analytes, including nucleic acids, proteins and polypeptides. Compositions include nucleic acid compositions and protein compositions with affinity binding pairs, including metal binding peptides and immobilized metals, or peptide affinity groups.
Type:
Application
Filed:
January 4, 2021
Publication date:
June 3, 2021
Applicant:
Enzo Biochem, Inc.
Inventors:
Elazar Rabbani, Jannis G. Stavrianopoulos, James J. Donegan, Wayne Patton, Juan Carcamo
Abstract: The present disclosure provides reactive quencher dyes that can be used in the detection and/or quantification of desirable target molecules, such as proteins, nucleic acids and various cellular organelles. These dyes are essentially non-fluorescent but are efficient quenchers of various fluorescent dyes. Also, provided are methods of using the dyes, bio-probes incorporating dyes and methods of using the bio-probes. The quencher dyes described herein are modified to provide beneficial properties.
Abstract: The invention provides cell culture compositions for regulatory T-cells that include particular synthetic peptides. Also provided are methods of treating autoimmune diseases such as age-related macular degeneration and uveitis with regulatory T-cells prepared using said compositions.
Type:
Application
Filed:
September 9, 2020
Publication date:
March 11, 2021
Applicant:
Enzo Biochem, Inc.
Inventors:
Robert Nussenblatt, Baoying LIU, Lai WEI, Elazar RABBANI, James J. DONEGAN
Abstract: Provided are immunomodulatory pharmaceutical and non-pharmaceutical compositions that include alpha-synuclein and at least one preselected antigen, such as at least one preselected peptide antigen or immunogen. Also provided are methods for modulating immune activity toward at least one preselected antigen in an at least substantially antigen-specific manner that include administering such a composition to a human patient or to a non-human mammalian subject. Still further provided are enhanced assay methods for quantifying antigen-specific cellular responses, such as cytokine release, to preselected antigens.
Type:
Application
Filed:
August 31, 2020
Publication date:
February 11, 2021
Applicant:
Enzo Biochem, Inc
Inventors:
Ante Tocilj, Jack Coleman, Elazar Rabbani, James J. Donegan
Abstract: Provided is a protein comprising an antibody binding site that binds to a sulfated epitope of a Wnt pathway protein that is not Wnt5A, Wnt11, or Wnt3a. Also provided is a composition comprising an isolated and purified Wnt pathway protein, where the protein is sulfated but not glycosylated. Additionally provided is a preparation of a Wnt pathway protein comprising at least one sulfation site and at least one glycosylation site, where all of the Wnt pathway protein in the preparation is glycosylated but not sulfated. Further provided is a composition comprising a peptide less than 75 amino acids or amino acid analogs, the peptide consisting of a fragment of a Wnt pathway protein, wherein the fragment is sulfated. A modified Wnt pathway protein comprising a sulfation site that is not present in the native Wnt pathway protein is also provided. Also provided is a method of detecting or quantifying a sulfated Wnt pathway protein in a preparation.
Abstract: The invention provides methods and compositions for treating cancers and myeloproliferative disorders using sphingosine kinase-1 inhibitors, such as SK1-I, and selective sphingosine-1-phosphate receptor agonists, such as ozanimod.
Abstract: The invention provides methods and compositions for treating cancers and myeloproliferative disorders using sphingosine kinase-1 inhibitors, such as SK1-I, and selective sphingosine-1-phosphate receptor agonists, such as ozanimod.
Abstract: The present disclosure provides reactive quencher dyes that can be used in the detection and/or quantification of desirable target molecules, such as proteins, nucleic acids and various cellular organelles. These dyes are essentially non-fluorescent but are efficient quenchers of various fluorescent dyes. Also, provided are methods of using the dyes, bio-probes incorporating dyes and methods of using the bio-probes. The quencher dyes described herein are modified to provide beneficial properties.
Abstract: The invention provides immunomodulatory pharmaceutical compositions that include a synthetic peptide and one or more immune tolerance enhancers.
Type:
Application
Filed:
June 2, 2020
Publication date:
November 26, 2020
Applicant:
Enzo Biochem, Inc.
Inventors:
Robert Nussenblatt, Baoying Liu, Lai Wei, Elazar Rabbani, James J. Donegan
Abstract: The present invention relates to the field of therapeutic methods, compositions and uses thereof, that affect, directly or indirectly, the behavior of LRP receptors. These compositions and methods result in the treatment of inflammatory, immunological and metabolic conditions. More particularly, the methods and compositions of the invention are directed to the identification of small molecules, drugs and/or pharmacological agents that affect the Wnt pathway by affecting normal complex formation among various signaling receptors, the LRP5 and LRP6 receptor, and related ligands.
Type:
Application
Filed:
April 21, 2020
Publication date:
November 19, 2020
Applicant:
ENZO BIOCHEM, INC
Inventors:
Elazar Rabbani, Xiaofeng Li, Dakai Liu, Yazhou Zhang, Richard Jin, Riddhi Bhattacharyya, Wei Cheng, James J. Donegan
Abstract: a The invention provides nucleic acid hybridization probes having improved detectability that include a plurality of first segments consecutively complementary to a target nucleic acid sequence and, between neighboring first segments, a nucleic acid spacer segment which is not complementary to the target nucleic acid sequence and which may include labeled nucleic acid residues. Also provided by the invention are methods for making the probes, methods for using the probes, and compositions of matter that include the probes hybridized to target nucleic acid molecules.
Type:
Application
Filed:
July 6, 2020
Publication date:
October 22, 2020
Applicant:
ENZO BIOCHEM, INC.
Inventors:
ELAZAR RABBANI, JAMES J. DONEGAN, JACK COLEMAN, MAURIZIO MAURO
Abstract: Provided are antibodies that bind to: a sulfonated epitope of the protein Sclerostin, to Sclerostin portions comprising a sulfonated amino acid and to dimerized forms of Sclerostin. Further provided are compositions and peptides comprising a sulfonated epitope of sclerostin. Also provided by this invention are methods for production of such antibodies, both active and passive, and methods for identifying antibodies specific for sulfonation sites in Sclerostin and other antibodies which discriminate between sulfonated and unsulfonated forms of sclerostin. Physical and virtual screening processes are provided in this invention for identifying compounds which disrupt or inhibit sulfonation and the interaction between Sclerostin and binding partners. The antibodies and compositions of the present invention are useful in diagnostic and therapeutic applications directed to Sclerostin-related disorders.
Abstract: The invention provides methods and compositions for treating cancers and myeloproliferative disorders using sphingosine kinase-1 inhibitors, such as SK1-I, and selective sphingosine-1-phosphate receptor agonists, such as ozanimod.
Abstract: The invention provides methods and compositions for treating cancers and myeloproliferative disorders using sphingosine kinase-1 inhibitors, such as SK1-I, and selective sphingosine-1-phosphate receptor agonists, such as ozanimod.
Abstract: The invention provides immunomodulatory pharmaceutical compositions that include a synthetic peptide and one or more immune tolerance enhancers.
Type:
Grant
Filed:
June 13, 2019
Date of Patent:
July 14, 2020
Assignee:
Enzo Biochem, Inc.
Inventors:
Robert Nussenblatt, Baoying Liu, Lai Wei, Elazar Rabbani, James J. Donegan
Abstract: The invention provides methods for synthesizing the compound (2R,3S,4E)-N-methyl-5-(4?-pentylphenyl)-2-aminopent-4-ene-1,3-diol, also known as SK1-I, and intermediate compounds used in its synthesis.
Abstract: The invention provides methods and compositions for treating cancers and myeloproliferative disorders using sphingosine kinase-1 inhibitors, such as SK1-I, and selective sphingosine-1-phosphate receptor agonists, such as ozanimod.
Type:
Grant
Filed:
December 21, 2018
Date of Patent:
May 26, 2020
Assignee:
Enzo Biochem, Inc.
Inventors:
Elazar Rabbani, James J. Donegan, Paul Diamond